According to a story from Andre Eger, the drug developer Gilead recently had the misfortune to announce that its clinical trial testing an experimental drug for late stage nonalcoholic steatohepatitis…
Autoimmune hepatitis (AIH) is a rare condition which causes inflammation in the liver. It can lead to cirrhosis and ultimately, liver failure. The typical treatment for patients with the disease includes…
Nonalcoholic fatty liver disease (NAFLD) is a condition which causes fat to accumulate in the liver. Nonalcoholic steatohepatitis (NASH) is a severe form of the disease in which the patient also…
Nonalcoholic steatohepatitis (NASH), is condition most commonly caused by obesity or type 2 diabetes. It can result in fibrosis, complications in the lung and cardiac system, liver cancer, liver cirrhosis,…
According to a story from Proactive Investors, the biotechnology company Conatus Pharmaceuticals recently reported that the company's drug Emricasan failed to achieve the primary endpoint in a Phase 2b clinical…
Nonalcoholic fatty liver disease (NAFLD) is exactly what it sounds like. It's caused by a buildup of fat cells in the liver, resulting in many complications caused by the thickening…
According to a story from Health Canal, a team of researchers led by Dr. Mohammad Siddiqui of Virginia Commonwealth University (VCU) recently released a study which further highlights the relationship…
According to a story from tradeshownews.vporoom.com, the biopharmaceutical company Viking Therapeutics, Inc., has recently released the results from a Phase 2 clinical trial. This trial is testing the company's investigational therapeutic…
A new published research study shows that women who breastfeed at least one child for six months or more are at a lower risk of having nonalcoholic fatty liver…
According to a story from Markets Insider, the biotechnology company Innovate Biopharmaceuticals, Inc., recently announced encouraging proof-of-concept data for its lead medical product larazotide acetate. This experimental drug appears to…
According to a story from globenewswire.com, the drug developers Pfizer and Novartis have recently announced the beginning of a collaborative effort to test new potential therapies for nonalcoholic steatohepatitis (NASH).…
According to a story from Healio, Dr. Monica Konerman recently gave a presentation about the importance of lifestyle changes in treating nonalcoholic fatty liver disease and its rarer and more…
According to a story from Healio, recent testing has found that FibroScan, a form of medical imaging, is capable of detecting nonalcoholic steatohepatitis earlier than it would be possible to…
According to a story from Xcomony, the tech startup Glympse Bio has been developing a sensor technology that it claims will allow doctors to detect a variety of diseases earlier…
Based on reports from PRNewswire, there appears to be a rising concern in both the number of cases and the amount of global concern about NASH. NASH stands for Nonalcoholic…
For a long time, researchers thought that chronic liver inflammation was the driving force of cancer, because the inflammation allows the cancer cells to divide, preventing them from dying. But…
According to a story from globenewswire.com, the drug development company Galectin Therapeutics, Inc., recently announced its plans to go forward with Phase 3 trials for GR-MD-02. The company is dedicated…
According to NBC Right Now, the liver disease advocacy organization called The American Liver Foundation is launching an online platform designed to pair liver disease patients to clinical trials. The website,…
According to a story from ibdnewstoday.com, a recent study from Italy suggests that people with severe cases of inflammatory bowel disease are more likely to develop non-alcoholic fatty liver disease.…
Debora Chambless was on a steady decline. She suffers from nonalcoholic steatohepatitis, the most extreme form of non-alcoholic fatty liver disease. Debora and her husband Bill are active churchgoers, and…
In the UK, Newcastle University and Pfizer are collaborating on a $39.9 million-dollar funded project aimed at developing greater tools for testing patients at the most risk for non-alcoholic fatty…
When it comes to the topic of severe fatty liver disease there is good news and bad news. In the spirit of leaving on a good note, let’s get to…
The scenario is much more common today than in years past. A patient who doesn't abuse alcohol or have chronic hepatitis is admitted to the hospital, many times the ICU,…
To put it lightly, the phrase “fight like a girl” isn’t exactly music to my ears. But when women take ownership of the saying, re-claim it in a way, that’s…
Feeling distraught because your child may have nonalcoholic fatty liver disease (NAFLD)? Well you should be—but keep in mind there is still time for hope. I read an easily digestible…
© Copyright Patient Worthy
